{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:22:41Z","timestamp":1793956961191,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04688-x","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T03:03:36Z","timestamp":1765508616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of steroids glucocorticoids compared with supportive therapy for IgA nephropathy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Hao","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"1","key":"4688_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2020.10.015","volume":"6","author":"M Shi","year":"2021","unstructured":"Shi M, et al. Increased lifetime risk of ESRD in Familial IgA nephropathy. Kidney Int Rep. 2021;6(1):91\u2013100.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"4688_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","volume":"93","author":"H Suzuki","year":"2018","unstructured":"Suzuki H, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93(3):700\u20135.","journal-title":"Kidney Int"},{"issue":"5","key":"4688_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I. Epidemiology of IgA nephropathy: A global perspective. Semin Nephrol. 2018;38(5):435\u201342.","journal-title":"Semin Nephrol"},{"issue":"1","key":"4688_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12882-024-03713-9","volume":"25","author":"AAA Elnaga","year":"2024","unstructured":"Elnaga AAA, et al. Safety and efficacy of sparsentan versus Irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. BMC Nephrol. 2024;25(1):316.","journal-title":"BMC Nephrol"},{"issue":"4","key":"4688_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN. IgA Nephrop Clin J Am Soc Nephrol. 2017;12(4):677\u201386.","journal-title":"IgA Nephrop Clin J Am Soc Nephrol"},{"issue":"7","key":"4688_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","volume":"179","author":"SJ Barbour","year":"2019","unstructured":"Barbour SJ, et al. Evaluating a new international Risk-Prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942\u201352.","journal-title":"JAMA Intern Med"},{"issue":"Suppl 2","key":"4688_CR7","doi-asserted-by":"publisher","first-page":"ii40","DOI":"10.1093\/ckj\/sfad224","volume":"16","author":"F Locatelli","year":"2023","unstructured":"Locatelli F, Vecchio LD, Ponticelli C. Systemic and targeted steroids for the treatment of IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii40\u20136.","journal-title":"Clin Kidney J"},{"issue":"10084","key":"4688_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstrom","year":"2017","unstructured":"Fellstrom BC, et al. Targeted-release Budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327.","journal-title":"Lancet"},{"issue":"23","key":"4688_CR9","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225\u201336.","journal-title":"N Engl J Med"},{"issue":"10\u201311","key":"4688_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1159\/000519812","volume":"52","author":"MG Wong","year":"2021","unstructured":"Wong MG, et al. The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics. Am J Nephrol. 2021;52(10\u201311):827\u201336.","journal-title":"Am J Nephrol"},{"issue":"6","key":"4688_CR11","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1681\/ASN.2011111112","volume":"23","author":"J Lv","year":"2012","unstructured":"Lv J, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012;23(6):1108\u201316.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4688_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.21037\/atm-22-1028","volume":"10","author":"Q Feng","year":"2022","unstructured":"Feng Q, et al. Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment. Annals Translational Med. 2022;10(6):355\u2013355.","journal-title":"Annals Translational Med"},{"key":"4688_CR13","doi-asserted-by":"crossref","unstructured":"Liu T, et al. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy. Medicine, 2021;100(8).","DOI":"10.1097\/MD.0000000000024541"},{"issue":"5","key":"4688_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, et al. Effect of oral Methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432\u201342.","journal-title":"JAMA"},{"issue":"1","key":"4688_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12882-024-03481-6","volume":"25","author":"M Rivedal","year":"2024","unstructured":"Rivedal M, et al. Use of corticosteroids in Norwegian patients with Immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study. BMC Nephrol. 2024;25(1):42.","journal-title":"BMC Nephrol"},{"issue":"10084","key":"4688_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, et al. Targeted-release Budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327.","journal-title":"Lancet"},{"issue":"3\u20134","key":"4688_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1081\/JDI-100104732","volume":"23","author":"F Locatelli","year":"2001","unstructured":"Locatelli F, et al. Role of proteinuria reduction in the progression of IgA nephropathy. Ren Fail. 2001;23(3\u20134):495\u2013505.","journal-title":"Ren Fail"},{"issue":"2","key":"4688_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of Budesonide for the treatment of primary Immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391\u2013402.","journal-title":"Kidney Int"},{"issue":"12","key":"4688_CR19","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/ndt\/gfn394","volume":"23","author":"R Katafuchi","year":"2008","unstructured":"Katafuchi R, et al. The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transpl. 2008;23(12):3915\u201320.","journal-title":"Nephrol Dial Transpl"},{"issue":"10405","key":"4688_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, et al. Efficacy and safety of a targeted-release formulation of Budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370.","journal-title":"Lancet"},{"issue":"3","key":"4688_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10157-004-0298-7","volume":"8","author":"T Moriyama","year":"2004","unstructured":"Moriyama T, et al. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function. Clin Exp Nephrol. 2004;8(3):237\u201342.","journal-title":"Clin Exp Nephrol"},{"issue":"19","key":"4688_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, et al. Effect of oral Methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888\u201398.","journal-title":"JAMA"},{"issue":"3","key":"4688_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10157-003-0236-0","volume":"7","author":"T Uzu","year":"2003","unstructured":"Uzu T, et al. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria. Clin Exp Nephrol. 2003;7(3):210\u20134.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"4688_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5935\/01012800.20130005","volume":"35","author":"N Novaretti","year":"2013","unstructured":"Novaretti N, et al. Corticotherapy response in primary IgA nephropathy. J Bras Nefrol. 2013;35(1):27\u201334.","journal-title":"J Bras Nefrol"},{"issue":"9156","key":"4688_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883\u20137.","journal-title":"Lancet"},{"key":"4688_CR26","doi-asserted-by":"publisher","first-page":"585859","DOI":"10.3389\/fmed.2020.585859","volume":"7","author":"A Qin","year":"2020","unstructured":"Qin A, et al. Corticosteroids improve renal survival: A retrospective analysis from Chinese patients with Early-Stage IgA nephropathy. Front Med (Lausanne). 2020;7:585859.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"4688_CR27","first-page":"4103","volume":"18","author":"Y Tang","year":"2018","unstructured":"Tang Y, et al. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single-center cohort study. Mol Med Rep. 2018;18(4):4103\u201312.","journal-title":"Mol Med Rep"},{"issue":"5","key":"4688_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/nep.14269","volume":"29","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Corticosteroid in IgA nephropathy with moderate proteinuria: A retrospective cohort study. Nephrol (Carlton). 2024;29(5):268\u201377.","journal-title":"Nephrol (Carlton)"},{"issue":"1","key":"4688_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4688_CR30","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0272-6386(03)00194-X","volume":"41","author":"R Katafuchi","year":"2003","unstructured":"Katafuchi R, et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003;41(5):972\u201383.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4688_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000330189","volume":"34","author":"T Moriyama","year":"2011","unstructured":"Moriyama T, et al. Comparison of steroids and angiotensin receptor blockers for patients with advanced IgA nephropathy and impaired renal function. Am J Nephrol. 2011;34(3):233\u201340.","journal-title":"Am J Nephrol"},{"issue":"4","key":"4688_CR32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1159\/000492592","volume":"43","author":"L Tan","year":"2018","unstructured":"Tan L, et al. Combined immunosuppressive treatment May improve Short-Term renal outcomes in Chinese patients with advanced IgA nephropathy. Kidney Blood Press Res. 2018;43(4):1333\u201343.","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"4688_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s10157-008-0036-7","volume":"12","author":"M Koike","year":"2008","unstructured":"Koike M, et al. Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center. Clin Exp Nephrol. 2008;12(4):250\u20135.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"4688_CR34","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1038\/s41598-020-63170-w","volume":"10","author":"J Tan","year":"2020","unstructured":"Tan J, et al. The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis. Sci Rep. 2020;10(1):6062.","journal-title":"Sci Rep"},{"issue":"6","key":"4688_CR35","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1159\/000496000","volume":"43","author":"P Yang","year":"2018","unstructured":"Yang P, et al. Efficacy and safety of agents in IgA nephropathy: an update network Meta-Analysis. Kidney Blood Press Res. 2018;43(6):1890\u20137.","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"4688_CR36","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2012","unstructured":"Le W, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transpl. 2012;27(4):1479\u201385.","journal-title":"Nephrol Dial Transpl"},{"key":"4688_CR37","doi-asserted-by":"crossref","unstructured":"Sands JM, et al. Corticosteroid treatment influences TA-Proteinuria and renal survival in IgA nephropathy. Plos One. 2016;11(7).","DOI":"10.1371\/journal.pone.0158584"},{"issue":"1","key":"4688_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygcen.2010.07.004","volume":"169","author":"P Smets","year":"2010","unstructured":"Smets P, et al. Cushing\u2019s syndrome, glucocorticoids and the kidney. Gen Comp Endocrinol. 2010;169(1):1\u201310.","journal-title":"Gen Comp Endocrinol"},{"issue":"2","key":"4688_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2010","unstructured":"McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dialysis Transplantation. 2010;26(2):414\u201330.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"5","key":"4688_CR40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ki.2013.210","volume":"84","author":"SJ Barbour","year":"2013","unstructured":"Barbour SJ, et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013;84(5):1017\u201324.","journal-title":"Kidney Int"},{"issue":"8","key":"4688_CR41","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1517\/14656566.2015.1038238","volume":"16","author":"L Tian","year":"2015","unstructured":"Tian L, et al. The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up. Expert Opin Pharmacother. 2015;16(8):1137\u201347.","journal-title":"Expert Opin Pharmacother"},{"key":"4688_CR42","doi-asserted-by":"crossref","unstructured":"Han S, et al. Efficacy and safety of immunosuppressive monotherapy agents for IgA nephropathy: a network meta-analysis. Front Pharmacol. 2021;11.","DOI":"10.3389\/fphar.2020.539545"},{"key":"4688_CR43","doi-asserted-by":"crossref","unstructured":"Song Y-H, et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol. 2017;18(1).","DOI":"10.1186\/s12882-017-0467-z"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04688-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04688-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04688-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T18:29:23Z","timestamp":1768847363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04688-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4688"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04688-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}